#News for #Investors and #Media: This week, BeiGene will join researchers from around the globe as they share new developments in Waldenstr?m macroglobulinemia (WM), a rare type of non-Hodgkin lymphoma which starts in the B-cells, for the 12th International Workshop on Waldenstrom’s Macroglobulinemia (#IWWM12). This year, BeiGene will share 7 presentations highlighting our BTK inhibitor and pipeline assets. Read our release for an overview of our planned presentations: https://bit.ly/3U7hexp
关于我们
BeiGene is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeiGene, please visit www.beigene.com and follow us on LinkedIn, X (formerly known as Twitter) and Facebook.
- 网站
-
https://www.beigene.com
BeiGene的外部链接
- 所属行业
- 生物技术研究
- 规模
- 超过 10,001 人
- 总部
- Cambridge，MA
- 类型
- 上市公司
- 创立
- 2010
- 领域
- targeted therapy、immuno-oncology、hematology、oncology和cancer
地点
BeiGene员工
-
Andrew Harmon
Clinical recruiter at BeiGene
-
Roger Ralph TSCHOPP M.D., M.Sc.
Senior Medical Director, Global Medical Affairs at BeiGene
-
Scott Carter
VP, Associate General Counsel, Business Development at BeiGene
-
Alex Emanuel
Healthcare marketer, commercial operations and analytics professional
动态
-
We at BeiGene are honoured to be a finalist for the Health Industry Hub's Catalysts for Change Award in Visionary Leadership! We are grateful for this recognition and the opportunity to contribute to the vital discussions on advancing our healthcare system to better meet patient needs.
-
-
At BeiGene, we believe our long-term success relies on building a culture and workforce that embraces diverse perspectives and experiences. This is what enables us to innovate and achieve breakthroughs for patients. This Global Diversity Awareness Month, we reaffirm our commitment to fostering an environment that reflects and supports the diverse communities of patients we serve, and the unique qualities that each colleague brings to BeiGene. Learn more at https://bit.ly/3RhIrfx. #GlobalDiversityAwarenessMonth #DEIB?
-
-
We announced that our immunotherapy is now available for eligible patients in Switzerland. The therapy is approved for the second-line treatment of advanced or metastatic #ESCC after prior platinum-based systemic therapy, who have not received immune checkpoint inhibitor therapy. In addition to our BTK inhibitor, this is our second therapy available in Switzerland and another example of our broad commitment to bringing innovative #cancer therapies to more patients across geographies.
-
-
On Global Mental Health Day, we reaffirm our commitment to making mental health and emotional wellness an integral part of quality cancer care.? ? Through our Talk About It program, we offer essential tools and resources for individuals living with cancer, their caregivers, and healthcare providers. Together, we can navigate the emotional challenges that go beyond the physical journey of cancer. ? Discover how we can support you or a loved one at https://bit.ly/3TZlNtG. #GlobalMentalHealthDay #TalkAboutIt #CancerCare
-
-
At BeiGene, we’re honored to partner with The Leukemia & Lymphoma Society for #LightTheNight walks happening in communities across the country. Meet Nick Chervenak, MPA, Sales Leader, Greater Northeast Division, walking in honor of his father, who bravely fought leukemia. Together, we’re lighting up the night and supporting those impacted by blood cancers.? Find a walk near you and join us in bringing light to the darkness of #cancer: https://bit.ly/3XETtPu. #WhyIWalk #TeamBeiGene
-
This National Disabilities Employment Awareness Month, we celebrate the achievements and contributions of individuals with disabilities while raising awareness about the importance of inclusivity and accessibility. Every person has unique strengths to share, and it’s essential that we foster environments where everyone can thrive.? ? Learn more about our commitment to diversity, equity, inclusion, and belonging at https://bit.ly/3zY1CFq. #NDEAM #DEIB
-
-
We’re proud to share Vizient, Inc has recognized BeiGene with the 2024 Pharmacy Strategic Excellence Award! This award highlights the success and commitment of our Market Access team in empowering Vizient provider customers to optimize cost, quality and market performance to ultimately improve healthcare for patients. Learn more:?https://bit.ly/4dx4maD
-
-
#News for #Investors and #Media: BeiGene announces availability of our PD-1 inhibitor in the U.S. for eligible patients with esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy that did not include a PD-(L)1 inhibitor. Learn more about our commitment to bringing this important therapy to patients.? https://bit.ly/4dA8I0T
-
#LungCancer is the most common cancer diagnosed globally, which is why we continue to advance our research in this area. Data from a Phase 3 study of our PD-1 inhibitor in advanced squamous NSCLC was recently published in ESMO Open (a journal from ESMO - European Society for Medical Oncology) highlighting long-term follow-up results. Learn more: https://bit.ly/4ezbzIM
-